UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 579

Sortiert nach

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi125-vi132

2013

Link zum Volltext

Verfügbarkeit prüfen

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials

Annals of oncology, 2015-04, Vol.26 (4), p.715-724

2015

Link zum Volltext

Verfügbarkeit prüfen

Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk

Annals of oncology, 2014-05, Vol.25 (5), p.1059-1064

2014

Link zum Volltext

Verfügbarkeit prüfen

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries

Annals of oncology, 2012-04, Vol.23 (4), p.853-859

2012

Link zum Volltext

Verfügbarkeit prüfen

Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v140-v146

2010

Link zum Volltext

Verfügbarkeit prüfen

A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours

Annals of oncology, 2005-07, Vol.16 (7), p.1152-1159

2005

Link zum Volltext

Verfügbarkeit prüfen

Testicular seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of oncology, 2009-05, Vol.20 (suppl-4), p.iv83-iv88

2009

Link zum Volltext

Verfügbarkeit prüfen

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

Annals of oncology, 2018-10, Vol.29, p.viii714-viii715

2018

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Annals of oncology, 2011-05, Vol.22 (5), p.1054-1061

2011

Link zum Volltext

Verfügbarkeit prüfen

Pancreatic cancer treatment and research: an international expert panel discussion

Annals of oncology, 2011-07, Vol.22 (7), p.1500-1506

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

British journal of cancer, 2013-04, Vol.108 (6), p.1316-1323

2013

Link zum Volltext

Verfügbarkeit prüfen

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Annals of oncology, 2016-12, Vol.27 (12), p.2203-2209

2016

Link zum Volltext

Verfügbarkeit prüfen

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Annals of oncology, 2013-06, Vol.24 (6), p.1580-1587

2013

Link zum Volltext

Verfügbarkeit prüfen

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Annals of oncology, 2009-06, Vol.20 (suppl-7), p.vii1-vii6

2009

Link zum Volltext

Verfügbarkeit prüfen

Interdisciplinary care programme to improve self‐management for cancer patients undergoing stem cell transplantation: a prospective non‐randomised intervention study

European journal of cancer care, 2017-07, Vol.26 (4), p.e12458-n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

Extragonadal germ cell tumors

Annals of oncology, 2002-01, Vol.13 (suppl-4), p.265-272

SCHMOLL, H.-J

2002

Link zum Volltext

Verfügbarkeit prüfen

Quality assurance in the treatment of colorectal cancer: the EURECCA initiative

Annals of oncology, 2014-08, Vol.25 (8), p.1485-1492

2014

Link zum Volltext

Verfügbarkeit prüfen

Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v147-v154

2010

Link zum Volltext

Verfügbarkeit prüfen

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Annals of oncology, 2011-06, Vol.22, p.v1-v9

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

Annals of oncology, 2006-06, Vol.17 (6), p.1000-1006

2006

Link zum Volltext

Verfügbarkeit prüfen

Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells

Cellular and molecular life sciences : CMLS, 2009-02, Vol.66 (3), p.495-503

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4083-4091

2003

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group

Annals of oncology, 2008-08, Vol.19 (8), p.1442-1449

2008

Link zum Volltext

Verfügbarkeit prüfen

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination

Bone marrow transplantation (Basingstoke), 2011-06, Vol.46 (6), p.784-789

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 579

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(473)
Mit Volltextzugriff
(501)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(310)
Science & Technology
(254)
Life Sciences & Biomedicine
(251)
Oncology
(220)
Male
(193)
Biological And Medical Sciences
(160)
Medical Sciences
(157)
Adult
(118)
Pharmacology. Drug Treatments
(109)
Middle Aged
(107)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(105)
Female
(95)
Antineoplastic Agents
(89)
Chemotherapy
(86)
Tumors
(71)
Aged
(70)
Testicular Neoplasms - Drug Therapy
(60)
Combined Modality Therapy
(58)
Treatment Outcome
(49)
Prognosis
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials

Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries

Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours

Testicular seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Pancreatic cancer treatment and research: an international expert panel discussion

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Interdisciplinary care programme to improve self‐management for cancer patients undergoing stem cell transplantation: a prospective non‐randomised intervention study

Extragonadal germ cell tumors

Quality assurance in the treatment of colorectal cancer: the EURECCA initiative

Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells

Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination

Suchergebnisse filtern